False Claims Act Statistical Year In Review — A Study In Contrasts

M
Mintz

Contributor

Mintz is a general practice, full-service Am Law 100 law firm with more than 600 attorneys. We are headquartered in Boston and have additional US offices in Los Angeles, Miami, New York City, San Diego, San Francisco, and Washington, DC, as well as an office in Toronto, Canada.
A year-end review of False Claims Act (FCA) case activity in 2022 reveals substantial growth in overall FCA enforcement activity, coupled with a decline in health care-related cases.
United States Food, Drugs, Healthcare, Life Sciences
To print this article, all you need is to be registered or login on Mondaq.com.

In this edition of EnforceMintz, we analyze trends in False Claims Act (FCA) investigations and lawsuits using data compiled by Mintz in its Qui Tam Database, the annual report of FCA statistics published by the Department of Justice (DOJ), and DOJ's discussion of FCA enforcement trends and recoveries that accompanied its annual report.

While the $2.2 billion in FCA recoveries in fiscal year (FY) 2022 fell below the prior year's amount of $5.6 billion, DOJ emphasized that it had obtained the second-highest number of FCA settlements in history in FY 2022. Health care FCA cases continued to generate the vast majority of FCA recoveries, accounting for $1.7 billion of the total FY 2022 recoveries. Qui tam FCA cases filed by relators exceeded 650 cases, and DOJ emphasized the continued significance of relators to drive FCA recoveries: over $1.9 billion out of $2.2 billion recovered in FY 2022 resulted from qui tam cases.

We also utilize the FCA statistics to provide insights on the trends and government priorities driving FCA cases and offer our predictions on the future of health care FCA cases. Click here to view the statistics and our analysis.

For additional health care enforcement analysis, view our recently released Health Care Enforcement Year In Review & 2023 Outlook, which reports on qui tam FCA cases, other government enforcement actions, and significant regulatory developments from the past year.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More